Exosens Stock Defies CAC 40 with a Soaring +102% Yearly Increase
Exosens significantly gains ground this Wednesday, driven by an upward revision of the price target by Deutsche Bank published today. The stock moves counter to a CAC 40 that is down 0.63% in the session. The specialist in sensors and optoelectronic components now shows an annual performance exceeding 100%.
Exosens Shares Rise Following Deutsche Bank's Price Target Increase
Exosens stock is up 2.59% at 65.30 euros this Wednesday morning, after closing at 63.65 euros the previous day. This rebound occurs as Deutsche Bank raised its price target from 55 to 60 euros, while maintaining its 'hold' recommendation. However, the new target remains 8.1% below the current price, reflecting the German institution's cautious view on the company's valuation. This movement is part of a contrasting sectoral context in Europe: Airbus is down 0.51% and Safran is down 1.70% in the session, while in the United States, RTX Corporation closed up 0.70% but Lockheed Martin dropped 1.31%. The release of Exosens's first quarter 2026 results, scheduled for April 27, will be the next catalyst for the stock.
Technical Analysis Indicates a Medium-Term Bullish Trend
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
From a technical standpoint, the price of 65.30 euros is above the 50-day moving average of 61.68 euros, confirming a medium-term bullish trend. The gap with the 200-day moving average, set at 48.93 euros, illustrates the extent of the progress made over a year, with performance reaching 102.8% over twelve months. The RSI, at 51, signals a balance between buying and selling pressures, with no overbought or oversold conditions. The stock oscillates in the median zone of its Bollinger Bands, with the upper bound at 73.61 euros and the lower bound at 55.57 euros. The next identifiable resistance threshold is positioned at 72.90 euros, while the major support is at 57.50 euros. Over the last three months, the progression reaches 13.57%, even though the weekly performance shows a slight decline of 0.99%. The monthly volatility, measured at 13.52%, indicates moderate variation amplitudes at this stage.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.